Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance

Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients

(2018) Liye He et al.   CANCER RESEARCH

Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels

(2017) Paolo G. Casali et al.   JOURNAL OF CLINICAL ONCOLOGY

Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer

(2017) Simon Vyse et al.   JOURNAL OF MOLECULAR BIOLOGY

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

(2017) Sydney M. Shaffer et al.   NATURE

Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions

(2017) Kyuho Han et al.   NATURE BIOTECHNOLOGY

Polypharmacology-based ceritinib repurposing using integrated functional proteomics

(2017) Brent M Kuenzi et al.   Nature Chemical Biology

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

(2017) Collin M Blakely et al.   NATURE GENETICS

Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution

(2017) Vanessa D. Jonsson et al.   Scientific Reports

Progress and impact of clinical phosphoproteomics on precision oncology

(2017) Nadia Lima et al.   Translational Cancer Research

Bayesian model of signal rewiring reveals mechanisms of gene dysregulation in acquired drug resistance in breast cancer

(2017) A. K. M. Azad et al.   PLoS One

Phosphoproteomics in translational research: a sarcoma perspective

(2016) J. Noujaim et al.   ANNALS OF ONCOLOGY

Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib

(2016) Aurelie Courtin et al.   BRITISH JOURNAL OF CANCER

Tumor microenvironment and cancer therapy resistance

(2016) Yu Sun   CANCER LETTERS

Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution

(2016) Boyang Zhao et al.   CELL

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

(2016) Aaron N Hata et al.   NATURE MEDICINE

The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies

(2016) Meng Michelle Xu et al.   TRENDS IN IMMUNOLOGY

Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors

(2016) Jocelyn P. Wong et al.   Cell Reports

Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data

(2015) Karen A. Ryall et al.   BIOINFORMATICS

HER2 testing and its predictive utility in anti-HER2 breast cancer therapy

(2015) Pooja P Advani et al.   Biomarkers in Medicine

FunPat: function-based pattern analysis on RNA-seq time series data

(2015) Tiziana Sanavia et al.   BMC GENOMICS

Drugging PI3K in cancer: refining targets and therapeutic strategies

(2015) Timothy A Yap et al.   CURRENT OPINION IN PHARMACOLOGY

Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib forEGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

(2015) Melissa L. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Toward understanding and exploiting tumor heterogeneity

(2015) Ash A Alizadeh et al.   NATURE MEDICINE

Exceptional responders—discovering predictive biomarkers

(2015) Naoko Takebe et al.   Nature Reviews Clinical Oncology

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains

(2015) Timothy J. Stuhlmiller et al.   Cell Reports

Prioritizing targets for precision cancer medicine

(2014) F. Andre et al.   ANNALS OF ONCOLOGY

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

(2014) Anthony W. Tolcher et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Predicting Cancer-Specific Vulnerability via Data-Driven Detection of Synthetic Lethality

(2014) Livnat Jerby-Arnon et al.   CELL

BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

(2014) H. Rizos et al.   CLINICAL CANCER RESEARCH

Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes

(2014) Mark D M Leiserson et al.   NATURE GENETICS

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

(2014) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells

(2014) Lesley A. Mathews Griner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models

(2014) Luke Whitesell et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Synthetic Lethality in ATM-Deficient RAD50-Mutant Tumors Underlies Outlier Response to Cancer Therapy

(2014) H. Al-Ahmadie et al.   Cancer Discovery

Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib

(2014) N. Wagle et al.   Cancer Discovery

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

(2014) M. Hidalgo et al.   Cancer Discovery

A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer

(2013) M. A. Socinski et al.   CLINICAL CANCER RESEARCH

Hsp90, an unlikely ally in the war on cancer

(2013) Jared J. Barrott et al.   FEBS Journal

Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

(2013) Justin F. Gainor et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetics and biomarkers in personalisation of lung cancer treatment

(2013) Rafael Rosell et al.   LANCET

Safety and feasibility of targeted agent combinations in solid tumours

(2013) Sook Ryun Park et al.   Nature Reviews Clinical Oncology

Addressing Genetic Tumor Heterogeneity through Computationally Predictive Combination Therapy

(2013) B. Zhao et al.   Cancer Discovery

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

(2013) H. Shi et al.   Cancer Discovery

Fitness Trade-offs Restrict the Evolution of Resistance to Amphotericin B

(2013) Benjamin Matteson Vincent et al.   PLOS BIOLOGY

Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

(2012) L. Xu et al.   CANCER RESEARCH

Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer

(2012) James S. Duncan et al.   CELL

Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer

(2012) Robert C. Doebele et al.   CLINICAL CANCER RESEARCH

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genome Sequencing Identifies a Basis for Everolimus Sensitivity

(2012) G. Iyer et al.   SCIENCE

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

(2011) Poulikos I. Poulikakos et al.   NATURE

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling

(2011) J. Chmielecki et al.   Science Translational Medicine

Protein Homeostasis and the Phenotypic Manifestation of Genetic Diversity: Principles and Mechanisms

(2010) Daniel F. Jarosz et al.   Annual Review of Genetics

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

(2010) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant

(2010) Wei-Sheng Huang et al.   JOURNAL OF MEDICINAL CHEMISTRY

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hsp90 and Environmental Stress Transform the Adaptive Value of Natural Genetic Variation

(2010) D. F. Jarosz et al.   SCIENCE

Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease

(2009) Leah E. Cowen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance

(2008) T. Shimamura et al.   CANCER RESEARCH

Inhibition of Hsp90 Down-regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel

(2008) A. Sawai et al.   CANCER RESEARCH

Harnessing genetically engineered mouse models for preclinical testing

(2007) Ana I. Robles et al.   CHEMICO-BIOLOGICAL INTERACTIONS